Antengene (HKSE:06996) Long-Term Debt : HK$193.78 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Antengene Long-Term Debt?

Antengene's Long-Term Debt for the quarter that ended in Jun. 2024 was HK$193.78 Mil.

Antengene's quarterly Long-Term Debt increased from Jun. 2023 (HK$109.38 Mil) to Dec. 2023 (HK$196.88 Mil) but then declined from Dec. 2023 (HK$196.88 Mil) to Jun. 2024 (HK$193.78 Mil).

Antengene's annual Long-Term Debt increased from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$33.50 Mil) and increased from Dec. 2022 (HK$33.50 Mil) to Dec. 2023 (HK$196.88 Mil).

Antengene Long-Term Debt Historical Data

The historical data trend for Antengene's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Long-Term Debt Chart

Antengene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

33.50

196.88

Antengene Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial							-	33.50	109.38	196.88	193.78

Antengene (HKSE:06996) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Antengene Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Antengene's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN

Website

https://www.antengene.com

Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Executives

Jay Mei 2023 Grat	2201 Interest of corporation controlled by you
Mei Jay	2201 Interest of corporation controlled by you
Begonia Investment Ltd.	2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Fountainvest China Capital Partners Gp3 Ltd.	2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p.	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner
Jay Mei 2020 Grat	2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines